Dung “Zung” Thai, M.D., Ph. D.

Zung has been Chief Medical Officer at BioTheryX since January 2020. He has held leadership roles at small and large companies including Amgen, Gilead Sciences, Atara, Arresto, Anza, and REMD Biotherapeutics where he led the development of small molecule and protein therapeutics in metabolism, oncology, and fibrotic diseases. Zung earned an A.B. from Cornell University and his M.D. and Ph.D. in pharmacology from the University of Pittsburgh School of Medicine. He was a fellow and clinical instructor in the department of clinical pharmacology at University of California, San Francisco. Zung was a post-doctoral fellow at the University of California, Berkeley and Carnegie Mellon University.